Ovid Therapeutics (OVID) Capital Expenditures (2016 - 2024)
Ovid Therapeutics (OVID) reported Capital Expenditures of -$26000.0 for Q4 2024, down 300.0% on a YoY basis from $13000.0 in Q1 2024, and down 141.27% quarter-over-quarter from $63000.0 in Q3 2024.
Ovid Therapeutics (OVID) Capital Expenditures (2016 - 2024) Analysis & Trends
Ovid Therapeutics has reported Capital Expenditures for 9 years, with the latest figure at -$26000.0 in Q4 2024.
- For the quarter ending Q4 2024, Capital Expenditures fell 300.0% year-over-year to -$26000.0; the trailing twelve-month figure through Sep 2025 stood at -$26000.0 (down 120.16% YoY), and the FY2024 full-year result was $90000.0, up 125.0% from the prior year.
- Capital Expenditures for Q4 2024 stood at -$26000.0, down from $63000.0 in the prior quarter.
- The five-year high for Capital Expenditures was $1.1 million in Q2 2022, with the low at -$834500.0 in Q3 2022.
- Historically, Capital Expenditures has averaged $90178.8 across 5 years, with a median of $24615.0 in 2022.
- The largest YoY upside for Capital Expenditures was 56040.81% in 2020 against a maximum downside of 14696.06% in 2020.
- Ovid Therapeutics' Capital Expenditures stood at $48598.0 in 2020, then tumbled by 112.58% to -$6115.0 in 2021, then soared by 16012.33% to $973039.0 in 2022, then plunged by 98.66% to $13000.0 in 2023, then slumped by 300.0% to -$26000.0 in 2024.
- The last three Capital Expenditures figures came in at -$26000.0 (Q4 2024), $63000.0 (Q3 2024), and $34000.0 (Q2 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 133.40 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -63,220.27 |
| 10 | Ovid Therapeutics | 311.83 Mn | 156.31 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -26,000.00 |
| Dec 31, 2024 | -26,000.00 |
| Sep 30, 2024 | 63,000.00 |
| Sep 30, 2024 | 63,000.00 |
| Jun 30, 2024 | 34,000.00 |
| Jun 30, 2024 | 34,000.00 |
| Mar 31, 2024 | 19,000.00 |
| Mar 31, 2024 | 19,000.00 |
| Dec 31, 2023 | 13,000.00 |
| Dec 31, 2023 | 13,000.00 |
| Sep 30, 2023 | -83,000.00 |
| Sep 30, 2023 | -83,000.00 |
| Jun 30, 2023 | 96,000.00 |
| Jun 30, 2023 | 96,000.00 |
| Mar 31, 2023 | 14,000.00 |
| Mar 31, 2023 | 14,000.00 |
| Dec 31, 2022 | 973,039.00 |
| Dec 31, 2022 | 973,039.00 |
| Sep 30, 2022 | -834,500.00 |
| Sep 30, 2022 | -834,500.00 |